The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Abstract
Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.Methods We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centres in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimisation technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m(2), intravenously) plus docetaxel (60 mg/m(2), intravenously; n=89), administered every 21 days for three to six cycles. The primary endpoint was progression-free survival. Survival analysis was done with the modified intention-to-treat population. This study is registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.Findings Five patients were excluded (two patients were found to have thyroid and colon cancer after randomisation, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel). Thus, 172 patients (86 in each group) were included in the survival analyses. The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel goup, with a median progression-free survival time of 9.2 months (95% CI 8.0-13.9) versus 6.3 months (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001). Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhoea were more frequent in the gefitinib group. Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.Interpretation Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.Funding West Japan Oncology Group (WJOG): a non-profit organisation supported by unrestricted donations from several pharmaceutical companies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [30]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [145]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [5]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [8]
In the citing paper
“Most patients whose tumors harbor exon 19 deletions or L858R EGFR activating mutations have radiographic responses to monotherapy with the reversible adenosine triphosphate (ATP)-competitive EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib 17–23 and the irreversible EGFR TKI afatinib 24.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [21]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [9]
In the citing paper
“Several other trials conducted in Asia confirmed the superiority of Gefitinib over chemotherapy in EGFR-mutated patients [16, 44, 64].”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [16]
In the citing paper
“Targeted therapies for these lung cancers were established based on 7 phase III randomized trials.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Randomized phase III trials have demonstrated the superiority of these TKI, in terms of progression free survival (PFS), to conventional chemotherapy in patients with lung cancers harboring EGFR mutations.5, 6, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Evidence of these common mutations has been developed in prospective trials: gefitinib, erlotinib and afatinib showed ORR of approximately 60% and PFS of 9–13 months.5, 6, 7, 8, 9, 10, 11”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [6]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [6]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [109]
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Self-citationKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,435
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Research works printed but not linked: 2
- Cappuzzo, 2009, Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study, J Thorac Oncol, 4
- Lee, 2009, A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung, J Thorac Oncol, 4
Cited by
Sorted by citations
Items 201–300 of 1,010
Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., Chou, T.-Y., Enriquez, M. L. D., Lee, G. K., Iqbal, J., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000422 · Cited by 182
Self-citationOu, S.-H. I. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.11.010 · Cited by 182
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.005 · Cited by 182
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.026 · Cited by 182
Self-citationCheng, Y., Murakami, H., Yang, P., He, J., Nakagawa, K., Kang, J. H., Kim, J.-H., Wang, X., Enatsu, S., Puri, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9218 · Cited by 182
Self-citationShah, R. N. H., & Lester, J. F. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 183
Yang, J., Zhou, C., Huang, Y.-S., Feng, J., Sun, L., Song, Y., Huang, C., Wu, G., Zhang, L., Cheng, Y., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30262-x · Cited by 181
Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F. R., Siggillino, A., Flacco, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a3a6b · Cited by 180
Sunaga, N., Shames, D. S., Girard, L., Peyton, M., Larsen, J. E., Imai, H., Soh, J., Sato, M., Yanagitani, N., Kaira, K., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0750 · Cited by 180
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Hata, A., Katakami, N., Yoshioka, H., Takeshita, J., Tanaka, K., Nanjo, S., Fujita, S., Kaji, R., Imai, Y., Monden, K., et al. (2013) · Cancer · doi:10.1002/cncr.28364 · Cited by 178
Self-citationBiomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 179
Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.010 · Cited by 176
Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176
Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., Hong, S., Wu, X., Qin, T., Liang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107161 · Cited by 175
Yang, J. J., Zhou, Q., Yan, H. H., Zhang, X. C., Chen, H. J., Tu, H. Y., Wang, Z., Xu, C. R., Su, J., Wang, B. C., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.456 · Cited by 175
Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.150 · Cited by 174
Ding, P. N., Lord, S. J., Gebski, V., Links, M. J., Bray, V., Gralla, R. J., Yang, J. C., & Lee, C. K. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2236 · Cited by 174
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S. R., Fidias, P., Temel, J. S., Heist, R. S., Shaw, A. T., McCarthy, P., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318262de4a · Cited by 173
Reck, M., Hagiwara, K., Han, B., Tjulandin, S., Grohé, C., Yokoi, T., Morabito, A., Novello, S., Arriola, E., Molinier, O., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.036 · Cited by 174
To, C., Beyett, T. S., Jang, J., Feng, W. W., Bahcall, M., Haikala, H. M., Shin, B. H., Heppner, D. E., Rana, J. K., Leeper, B. A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00351-8 · Cited by 176
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 171
Yang, J., Zhang, X., Su, J., Xu, C., Zhou, Q. H., Tian, H.-X., Xie, Z., Chen, H.-J., Huang, Y.-S., Jiang, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0699 · Cited by 171
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn, M., Sun, J., Lee, S., Ahn, J. S., & Park, K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1300656 · Cited by 170
Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170
Zhao, Y., Liu, J., Cai, X., Pan, Z., Liu, J., Yin, W., Chen, H., Xie, Z., Liang, H., Wang, W., et al. (2019) · BMJ · doi:10.1136/bmj.l5460 · Cited by 170
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 168
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Román, J. S., Morante, Z., Araujo, J. M., Gómez, H., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 167
Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., Yang, J.-J., Zhou, Q., Yan, H.-H., An, S.-J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0385 · Cited by 165
Yang, J., Chen, H., Yan, H., Zhang, X., Zhou, Q. H., Su, J., Wang, Z., Xu, C., Huang, Y.-S., Wang, B.-C., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.016 · Cited by 165
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 165
Wynes, M. W., Sholl, L. M., Dietel, M., Schuuring, E. M. D., Tsao, M., Yatabe, Y., Tubbs, R. R., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000115 · Cited by 165
Self-citationEngelhardt, H., Böse, D., Petronczki, M. P., Scharn, D., Bader, G., Baum, A., Bergner, A., Chong, E., Döbel, S., Egger, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01169 · Cited by 168
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Jacobsen, K., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony, C., Codony‐Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 162
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., Zhan, P., & Song, Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.12 · Cited by 163
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 161
Ha, S. Y., Choi, S., Cho, J. H., Choi, H. J., Lee, J., Jung, K., Irwin, D. L., Liu, X., Lira, M. E., Mao, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2925 · Cited by 160
Qin, K., Hou, H., Yu, L., & Zhang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-06805-5 · Cited by 161
Urata, Y., Katakami, N., Morita, S., Kaji, R., Yoshioka, H., Seto, T., Satouchi, M., Iwamoto, Y., Kanehara, M., Fujimoto, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4154 · Cited by 159
Self-citationHan, J., Lee, S.-H., Yoo, N. J., Hyung, L. S., Moon, Y. J., Yun, T., Kim, H. T., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2525 · Cited by 159
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158
Gregorc, V., Novello, S., Lazzari, C., Barni, S., Aieta, M., Mencoboni, M., Grossi, F., Pas, T. M. D., de Marinis, F., Bearz, A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70162-7 · Cited by 158
Burotto, M., Manasanch, E. E., Wilkerson, J., & Fojo, T. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0154 · Cited by 158
Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 158
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Zhang, J., Zhang, L., Su, X., Li, M., Xie, L., Malchers, F., Fan, S., Yin, X., Xu, Y., Liu, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2694 · Cited by 156
Soo, R. A., Lim, S. M., Syn, N. L. X., Teng, R. S. Y., Soong, R., Mok, T. S. K., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 156
Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 156
Ohe, Y., Imamura, F., Nogami, N., Okamoto, I., Kurata, T., Kato, T., Sugawara, S., Ramalingam, S. S., Uchida, H., Hodge, R. A., et al. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy179 · Cited by 156
Self-citationPeters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Maemondo, M., Minegishi, Y., Inoue, A., Kobayashi, K., Harada, M., Okinaga, S., Morikawa, N., Oizumi, S., Tanaka, T., Isobe, H., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318260de8b · Cited by 155
Self-citationHan, B., Tjulandin, S., Hagiwara, K., Normanno, N., Wulandari, L., Лактионов, К. К., Hudoyo, A., He, Y., Zhang, Y., Wang, M.-Z., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.021 · Cited by 155
Personalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 154
Self-citationUncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., et al. (2015) · Drugs · doi:10.1007/s40265-015-0434-6 · Cited by 152
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Brewer, M. R., Yun, C., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 152
McCoach, C. E., Blakely, C. M., Banks, K. C., Levy, B. P., Chue, B. M.-F., Raymond, V. M., Le, A. T., Lee, C. E., Diaz, J., Waqar, S. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2588 · Cited by 152
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 150
Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150
Self-citationIchihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
Kenmotsu, H., Wakuda, K., Mori, K. P., Kato, T., Sugawara, S., Kirita, K., Yoneshima, Y., Azuma, K., Nishino, K., Teraoka, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.006 · Cited by 150
Self-citationLiao, B.-C., Lin, C., & Yang, J. C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 149
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Self-citationPetrelli, F., Borgonovo, K., Cabiddu, M., Lonati, V., & Barni, S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.06.009 · Cited by 147
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 147
Tada, H., Mitsudomi, T., Misumi, T., Sugio, K., Tsuboi, M., Okamoto, I., Iwamoto, Y., Sakakura, N., Sugawara, S., Atagi, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01729 · Cited by 147
Self-citationLung Cancer Biomarkers: Present Status and Future Developments
Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0319-cr · Cited by 146
Integrating biomarkers in clinical trials
Buyse, M. E., Michiels, S., Sargent, D. J., Grothey, A. F., Matheson, A., & de Gramont, A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.120 · Cited by 144
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 145
Gadgeel, S. M., Ramalingam, S. S., & Kalemkerian, G. P. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.003 · Cited by 144
Suda, K., Mizuuchi, H., Maehara, Y., & Mitsudomi, T. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9391-7 · Cited by 143
Self-citationKhozin, S., Blumenthal, G. M., Jiang, X., He, K., Boyd, K. K., Murgo, A. J., Justice, R. L., Keegan, P., & Pazdur, R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0089 · Cited by 143
Sebastian, M., Papachristofilou, A., Weiß, C., Früh, M., Cathomas, R. L., Hilbe, W., Wehler, T., Rippin, G., Koch, S. D., Scheel, B., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-748 · Cited by 143
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142
Lee, J.-K., Hahn, S., Kim, D.-W., Suh, K. J., Keam, B., Kim, T. M., Lee, S.-H., & Heo, D. S. (2014) · JAMA · doi:10.1001/jama.2014.3314 · Cited by 141
Petrelli, F., Borgonovo, K., Cabiddu, M., & Barni, S. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.08.005 · Cited by 141
Han, B., Jin, B., Chu, T., Niu, Y., Dong, Y., Xu, J., Gu, A., Zhong, H., Wang, H., Zhang, X., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30806 · Cited by 141
De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138
Fujino, K., Motooka, Y., Hassan, W. A., Abdalla, M. O. A., Sato, Y., Kudoh, S., Hasegawa, K., Niimori‐Kita, K., Kobayashi, H., Kubota, I., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.08.018 · Cited by 138
Self-citationMolecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., et al. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01887.x · Cited by 137
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137
Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., Huang, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1094598 · Cited by 138
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study
Nosaki, K., Satouchi, M., Kurata, T., Yoshida, T., Okamoto, I., Katakami, N., Imamura, F., Tanaka, K., Yamane, Y., Yamamoto, N., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.007 · Cited by 136
Self-citationKawashima, Y., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00166-1 · Cited by 140
Self-citationGao, G., Ren, S., Li, A., Xu, J., Xu, Q., Su, C., Guo, J., Deng, Q., & Zhou, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.27396 · Cited by 135
Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., Xue, C., Zhang, J., Zhang, J., Ma, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085245 · Cited by 134
Leighl, N. B. (2012) · Current Oncology · doi:10.3747/co.19.1114 · Cited by 134
Kitazono, S., Fujiwara, Y., Tsuta, K., Utsumi, H., Kanda, S., Horinouchi, H., Nokihara, H., Yamamoto, N., Sasada, S., WATANABE, S.-I. J., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.008 · Cited by 134
Felip, E., Gridelli, C., Baas, P., Rosell, R., & Stahel, R. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr150 · Cited by 134
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Gridelli, C., de Marinis, F., Maïo, M. D., Cortinovis, D. L., Cappuzzo, F., & Mok, T. S. K. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.12.008 · Cited by 133
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Janjigian, Y. Y., Park, B. J., Zakowski, M. F., Ladanyi, M., Pao, W. J., D’Angelo, S. P., Kris, M. G., Shen, R., Zheng, J., & Azzoli, C. G. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318202bffe · Cited by 131
Cheung, H. W., Du, J., Boehm, J. S., He, F., Weir, B. A., Wang, X., Butaney, M., Sequist, L. V. D., Luo, B., Engelman, J. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0046 · Cited by 131
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 131
Metadata
- Authors
- Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., Asami, K., Katakami, N., Takada, M., Yoshioka, H., Shibata, K., Kudoh, S., Shimizu, E., Saito, H., Toyooka, S., Nakagawa, K., & Fukuoka, M.
- Affiliations
- Aichi Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Kindai University (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Osaka City General Hospital (JP)
- Osaka Habikino Medical Center (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Kobe City Medical Center General Hospital (JP)
- Kurashiki Central Hospital (JP)
- Kouseiren Takaoka Hospital (JP)
- Osaka City University (JP)
- Tottori University (JP)
- Okayama University (JP)
- Corresponding author
- Mitsudomi, Tetsuya
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 11
- Issue
- 2
- Pages
- 121-128
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2129360604
- Cited by
- 4,090
- References
- 34
- Citations by year
- 2026: 31 · 2025: 110 · 2024: 130 · 2023: 140 · 2022: 211 · 2021: 228 · 2020: 236 · 2019: 264 · 2018: 318 · 2017: 329 · 2016: 312 · 2015: 382 · 2014: 372 · 2013: 352 · 2012: 300
- FWCI
- 187.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- gefitinib, non-small cell lung cancer, EGFR mutation, EGFR tyrosine kinase inhibitors, exon 19 deletion, L858R mutation, progression-free survival, platinum-based chemotherapy, first-line therapy, myelosuppression, postoperative recurrence
- MeSH terms
- Docetaxel, Gefitinib, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Quinazolines, Taxoids, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
